Your browser doesn't support javascript.
loading
The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion.
Hu, Xin; Zhu, Bo; Vokes, Natalie; Fujimoto, Junya; Rojas Alvarez, Frank R; Heeke, Simon; Moreira, Andre L; Solis, Luisa M; Haymaker, Cara; Velcheti, Vamsidhar; Sterman, Daniel H; Pass, Harvey I; Cheng, Chao; Lee, Jack J; Zhang, Jianhua; Wei, Zhubo; Wu, Jia; Le, Xiuning; Ostrin, Edwin; Toumazis, Iakovos; Gibbons, Don; Su, Dan; Fukuoka, Junya; Antonoff, Mara B; Gerber, David E; Li, Chenyang; Kadara, Humam; Wang, Linghua; Davis, Mark; Heymach, John V; Hannash, Samir; Wistuba, Ignacio; Dubinett, Steven; Alexandrov, Ludmil; Lippman, Scott; Spira, Avrum; Futreal, Andrew P; Reuben, Alexandre; Zhang, Jianjun.
Afiliação
  • Hu X; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Zhu B; Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Vokes N; Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Fujimoto J; Hiroshima University Hospital, Hiroshima 7348551, Japan.
  • Rojas Alvarez FR; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Heeke S; Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Moreira AL; Department of Pathology, New York University Langone Medical Center, New York, 10012, USA.
  • Solis LM; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Haymaker C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Velcheti V; Department of Medical oncology, New York University, New York, 10012, USA.
  • Sterman DH; Department of Pulmonary, New York University, New York, 10012, USA.
  • Pass HI; Department of Cardiothoracic Surgery, New York University Langone Medical Center, New York, 10016, USA.
  • Cheng C; Department of Medicine, Epidemiology and Population Science, Baylor College of Medicine. Houston, TX, 77030, USA.
  • Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Zhang J; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Wei Z; Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Wu J; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Le X; Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Ostrin E; Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Toumazis I; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Gibbons D; Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Su D; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, China.
  • Fukuoka J; Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, 310022, China.
  • Antonoff MB; Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 8528523, Japan.
  • Gerber DE; Department of Thoracic & Cardiovasc Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Li C; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
  • Kadara H; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Wang L; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Davis M; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Heymach JV; Moores Cancer Center, UC San Diego School of Medicine, San Diego, CA, 92037, USA.
  • Hannash S; Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Wistuba I; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Dubinett S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Alexandrov L; Departments of Medicine and Pathology, University of California Los Angeles and Greater Los Angeles Healthcare System, Los Angeles, CA, 90095, USA.
  • Lippman S; Moores Cancer Center, UC San Diego School of Medicine, San Diego, CA, 92037, USA.
  • Spira A; Moores Cancer Center, UC San Diego School of Medicine, San Diego, CA, 92037, USA.
  • Futreal AP; Pathology & Laboratory Medicine, and Bioinformatics, Boston University, Boston, MA, 02215, USA.
  • Reuben A; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
  • Zhang J; Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Res Sq ; 2024 May 15.
Article em En | MEDLINE | ID: mdl-38798564
ABSTRACT
Studying lung adenocarcinoma (LUAD) early carcinogenesis is challenging, primarily due to the lack of LUAD precursors specimens. We amassed multi-omics data from 213 LUAD and LUAD precursors to identify molecular features underlying LUAD precancer evolution. We observed progressively increasing mutations, chromosomal aberrations, whole genome doubling and genomic instability from precancer to invasive LUAD, indicating aggravating chromosomal instability (CIN). Telomere shortening, a crucial genomic alteration linked to CIN, emerged at precancer stage. Moreover, later-stage lesions demonstrated increasing cancer stemness and decreasing alveolar identity, suggesting epithelial de-differentiation during early LUAD carcinogenesis. The innate immune cells progressively diminished from precancer to invasive LUAD, concomitant with a gradual recruitment of adaptive immune cells (except CD8+ and gamma-delta T cells that decreased in later stages) and upregulation of numerous immune checkpoints, suggesting LUAD precancer evolution is associated with a shift from innate to adaptive immune response and immune evasion mediated by various mechanisms.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Res Sq Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Res Sq Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos
...